MicroCap Investor Portfolio's Top Performer of the Week

January 14, 2011 -- The shares of this developer of a new class of cancer therapeutics are up 260% since Josh first recommended them to his subscribers. The stock is off to a strong start in 2011, surging 57% since December 31. The value of this biotech, which has a long-standing partnership with a leading biopharma and a healthy cash hoard, lies in the ability of its drugs to be used in combination therapies and its excellent prospects for attracting licensees.

Josh Levine's MicroCap Investor is a potential millionaire-maker service for investors with long time horizons and who are prepared for the volatile ups and downs of the microcap world.

The strategy for MicroCap Investor is simple: to focus on small, innovative companies representing the best pure plays in the fast-growing waves of change in biotechnology, cleantech, and other advanced and emerging technologies.


This is a great opportunity to put Josh's expertise to work for you in this often over-hyped and misrepresented -- yet dramatically under-researched -- part of the market, where severe market inefficiencies create opportunities for huge profits.

Josh's mission is to make sure the research is done, and done right. And that's just what he has been doing for years in the world of microcaps.

Learn more  http://www.levinesmicrocapinvestor.com/subscriptions/order/
or  http://www.levinesmicrocapinvestor.com/